Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Rating of “Moderate Buy” from Brokerages

Bicycle Therapeutics plc (NASDAQ:BCYC) has earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $47.88.

A number of equities research analysts have recently commented on BCYC shares. JMP Securities lowered their target price on Bicycle Therapeutics from $44.00 to $32.00 and set a “market outperform” rating on the stock in a research note on Wednesday, December 20th. Canaccord Genuity Group reiterated a “buy” rating and issued a $60.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, February 21st. HC Wainwright decreased their price target on shares of Bicycle Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a research note on Wednesday, February 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, April 10th.

Insider Activity at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 3,158 shares of Bicycle Therapeutics stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a total value of $75,191.98. Following the completion of the transaction, the chief executive officer now directly owns 387,270 shares in the company, valued at approximately $9,220,898.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders have sold 5,312 shares of company stock worth $126,139. 10.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its holdings in Bicycle Therapeutics by 250.2% in the 1st quarter. JPMorgan Chase & Co. now owns 9,903 shares of the company’s stock valued at $434,000 after purchasing an additional 7,075 shares during the period. Loomis Sayles & Co. L P raised its position in shares of Bicycle Therapeutics by 12.9% in the first quarter. Loomis Sayles & Co. L P now owns 643,775 shares of the company’s stock worth $28,249,000 after buying an additional 73,728 shares in the last quarter. UBS Group AG boosted its stake in Bicycle Therapeutics by 896.0% during the first quarter. UBS Group AG now owns 8,884 shares of the company’s stock valued at $389,000 after buying an additional 7,992 shares during the period. Vident Investment Advisory LLC grew its position in Bicycle Therapeutics by 20.3% during the first quarter. Vident Investment Advisory LLC now owns 21,572 shares of the company’s stock worth $947,000 after buying an additional 3,639 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new position in Bicycle Therapeutics in the 1st quarter worth about $341,000. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Trading Up 0.5 %

NASDAQ:BCYC opened at $21.93 on Wednesday. Bicycle Therapeutics has a 52 week low of $12.54 and a 52 week high of $28.91. The firm has a 50-day moving average price of $23.42 and a two-hundred day moving average price of $19.22. The company has a debt-to-equity ratio of 0.08, a quick ratio of 8.08 and a current ratio of 8.08. The firm has a market cap of $658.78 million, a price-to-earnings ratio of -4.27 and a beta of 0.89.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Tuesday, February 20th. The company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.07. The company had revenue of $5.33 million during the quarter, compared to the consensus estimate of $11.68 million. Bicycle Therapeutics had a negative return on equity of 57.80% and a negative net margin of 669.72%. On average, equities analysts expect that Bicycle Therapeutics will post -5.2 earnings per share for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.